SLG
BPMC

Stanley-Laman Group’s Blueprint Medicines BPMC Stock Holding History

Stanley-Laman Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,523
Closed -$605K – 225
2018
Q2 		$605K Buy
+9,523
New +$758K 0.14% 199

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Stanley-Laman Group's BPMC Position: Q3 2018 in Review

Stanley-Laman Group sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 9,523 shares — an estimated $605K sold.

Stanley-Laman Group first reported a position in BPMC in Q2 2018 and held it in 1 quarter. The position peaked at $605K in Q2 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • Stanley-Laman Group reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 9,523 Blueprint Medicines shares in Q3 2018, an estimated $605K.
  • Stanley-Laman Group first reported a position in Blueprint Medicines in Q2 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Blueprint Medicines position peaked at $605K in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.